Insmed Incorporated Shareholder Approvals and Director Elections

Details

2 to the 2019 Incentive Plan and elected Leo Lee and William H. Lewis as Class I directors until 2028. Shareholders also approved the 2024 compensation of named executive officers, ratified Ernst & Young LLP as the independent registered public accounting firm, and approved Amendment No. 2 to the 2019 Incentive Plan. These decisions were made at the Annual Meeting, where 166,336,150 shares were present or represented by proxy.

Items reported

About Insmed Inc.

Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.